World Hepatitis Day reminds us once again: the prevention and treatment of hepatitis must return to formal medical care, while lifestyle management must come down to concrete variables such as alcohol intake, body weight, sleep and exercise. This article separates the two pathways clearly, and explains what ProteinT MiMi™ can supplement — and what it cannot replace.
Protecting the liver: first, separate the two things
July 28 is World Hepatitis Day. The WHO 2026 theme is "Hepatitis: Let's Break It Down", and China's theme is "Social Co-Governance to Eliminate Hepatitis". Both themes point to the same thing: making prevention, testing, treatment and care truly accessible.
For individuals, hepatitis and liver disease risk should follow the formal medical pathway; recent states such as alcohol intake, diet, body weight, sleep and exercise are managed through daily routine. Drinking less and staying up less late are certainly worthwhile, but they cannot replace hepatitis testing; a single transaminase result also cannot on its own answer whether there is an infection, what the cause is, or what the overall condition of the liver is.
What should be examined, leave to medical institutions
If there is a relevant history of exposure, if a health check indicates abnormal liver function, or if there are obvious symptoms such as pronounced fatigue, reduced appetite, darker urine, or yellowing of the skin or the whites of the eyes, a visit to a formal medical institution should be made promptly. Doctors will make a judgment based on medical history, clinical presentation, liver biochemistry, and hepatitis B or C serology and nucleic acid testing, adding imaging examinations when necessary. No health management tool can replace this pathway.
What can be managed daily: break it down into concrete variables
In summer the daylight hours are long, and gatherings, late-night snacks, alcohol, delayed sleep and interrupted exercise easily stack up together. Alcohol is associated with liver disease risk; being overweight or obese, or having abnormal blood lipids or blood glucose, is also linked to metabolic-associated fatty liver disease.
Staying up late cannot simply be described as a direct cause of hepatitis or liver cancer, but long-term sleep insufficiency is indeed associated with chronic health problems such as obesity and diabetes. More realistically, staying up late often occurs together with late-night snacks, prolonged sitting and alcohol. Rather than speaking vaguely of "nourishing the liver", it is better to continuously record alcohol frequency, dinner and late-night snacks, body weight and waist circumference, sleep and exercise — change one or two items at a time, and look at the trend after a period.
Daily metabolic information: where can it supplement?
ProteinT MiMi™ is based on metabolic information in urine, providing a daily health management reference for recent states such as diet, routine, stress and exercise. It helps you sort out the matters currently most worth prioritizing, and also supports periodic re-testing and observation.
The boundary must be clear: MiMi™ does not test for hepatitis, does not screen for liver disease, and does not judge liver injury; what it provides is a supplementary reference on lifestyle and metabolic status. If abnormalities are found or disease risk exists, one should still return to formal medical examination and a doctor's judgment.
Walking both pathways steadily
Leave what should be examined to medical care, and put what can be changed back into daily life: do not delay when an abnormality is found, and do not rely on last-minute efforts for lifestyle. This is in fact what World Hepatitis Day is saying — scientific prevention and sustained management each play their part, and then you keep at it for the long term.
ProteinT / 谱天生物
INNOVATION FOR NEXT GENERATION
ProteinT is a national-level high-tech enterprise focused on the field of precision medicine multi-omics. As the lead unit of the Tianjin Key Laboratory of Clinical Multi-Omics, it took the lead in conducting "gene + protein + metabolism" multi-omics research, and its independently developed proteomics liquid biopsy technology is at an internationally leading level. Core team members come from well-known research institutions at home and abroad, including Yale University, the National Institutes of Health (USA), and the National Center for Protein Sciences.
Its R&D pipeline covers common single cancers and pan-cancer types such as liver, lung, gastric, esophageal, colorectal, and pancreatic cancers, and extends to major chronic diseases such as cardiovascular and cerebrovascular diseases, focusing on key research directions including early screening and early diagnosis, recurrence monitoring, and medication guidance. Its Umbrella™ clinical molecular database, with core intellectual property rights, contains more than 100,000 clinical sample records.
ProteinT is committed to continuous technological innovation and clinical translation of cutting-edge achievements, advancing precision medicine and exploring the infinite possibilities of human health.
